Radiation Oncology Journal

  • 제32권2호
  • /
  • Pages.63-69
  • /
  • 2014
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Patterns of failure and prognostic factors in resected extrahepatic bile duct cancer: implication for adjuvant radiotherapy

  • Koo, Tae Ryool (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Eom, Keun-Yong (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, In Ah (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Cho, Jai Young (Department of Surgery, Seoul National University College of Medicine) ;
  • Yoon, Yoo-Seok (Department of Surgery, Seoul National University College of Medicine) ;
  • Hwang, Dae Wook (Department of Surgery, Seoul National University College of Medicine) ;
  • Han, Ho-Seong (Department of Surgery, Seoul National University College of Medicine) ;
  • Kim, Jae-Sung (Department of Radiation Oncology, Seoul National University College of Medicine)
  • 투고 : 2014.04.23
  • 심사 : 2014.05.30
  • 발행 : 2014.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To find the applicability of adjuvant radiotherapy for extrahepatic bile duct cancer (EBDC), we analyzed the pattern of failure and evaluate prognostic factors of locoregional failure after curative resection without adjuvant treatment. Materials and Methods: In 97 patients with resected EBDC, the location of tumor was classified as proximal (n = 26) and distal (n = 71), using the junction of the cystic duct and common hepatic duct as the dividing point. Locoregional failure sites were categorized as follows: the hepatoduodenal ligament and tumor bed, the celiac artery and superior mesenteric artery, and other sites. Results: The median follow-up time was 29 months for surviving patients. Three-year locoregional progression-free survival, progression-free survival, and overall survival rates were 50%, 42%, and 52%, respectively. Regarding initial failures, 79% and 81% were locoregional failures in proximal and distal EBDC patients, respectively. The most common site was the hepatoduodenal ligament and tumor bed. In the multivariate analysis, perineural invasion was associated with poor locoregional progression-free survival (p = 0.023) and progression-free survival (p = 0.012); and elevated postoperative CA19-9 (${\geq}37U/mL$) did with poor locoregional progression-free survival (p = 0.002), progression-free survival (p < 0.001) and overall survival (p < 0.001). Conclusion: Both proximal and distal EBDC showed remarkable proportion of locoregional failure. Perineural invasion and elevated postoperative CA19-9 were risk factors of locoregional failure. In these patients with high risk of locoregional failure, adjuvant radiotherapy could be considered to improve locoregional control.

키워드

참고문헌

  1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-14. https://doi.org/10.1016/S0140-6736(05)67530-7
  2. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230:663-71. https://doi.org/10.1097/00000658-199911000-00008
  3. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-57. https://doi.org/10.1097/00000658-199709000-00004
  4. Edge SB; American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010.
  5. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689-700. https://doi.org/10.1002/cncr.11699
  6. Park JH, Choi EK, Ahn SD, et al. Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2011;79:696-704. https://doi.org/10.1016/j.ijrobp.2009.12.031
  7. Gwak HK, Kim WC, Kim HJ, Park JH. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2010;78:194-8. https://doi.org/10.1016/j.ijrobp.2009.07.003
  8. Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007;68:178-82. https://doi.org/10.1016/j.ijrobp.2006.11.048
  9. Urego M, Flickinger JC, Carr BI. Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 1999;44:121-6. https://doi.org/10.1016/S0360-3016(98)00509-4
  10. Morganti AG, Trodella L, Valentini V, et al. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 2000;46:913-9. https://doi.org/10.1016/S0360-3016(99)00487-3
  11. Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-22. https://doi.org/10.1200/JCO.2008.18.6288
  12. Kim TH, Han SS, Park SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys 2011;81:e853-9. https://doi.org/10.1016/j.ijrobp.2010.12.019
  13. He P, Shi JS, Chen WK, Wang ZR, Ren H, Li H. Multivariate statistical analysis of clinicopathologic factors influencing survival of patients with bile duct carcinoma. World J Gastroenterol 2002;8:943-6. https://doi.org/10.3748/wjg.v8.i5.943
  14. Nagakawa T, Mori K, Nakano T, et al. Perineural invasion of carcinoma of the pancreas and biliary tract. Br J Surg 1993;80: 619-21. https://doi.org/10.1002/bjs.1800800526
  15. Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996;223:384-94. https://doi.org/10.1097/00000658-199604000-00007
  16. Nakagohri T, Asano T, Kinoshita H, et al. Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg 2003;27:289-93. https://doi.org/10.1007/s00268-002-6696-7
  17. Harrison LB, Sessions RB, Hong WK. Head and neck cancer: a multidisciplinary approach. 3rd ed. Philadelphia, PA: Lipppincott Williams & Wilkins; 2009.
  18. Koh HK, Park HJ, Kim K, Chie EK, Min HS, Ha SW. Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery. Radiat Oncol J 2012;30:197-204. https://doi.org/10.3857/roj.2012.30.4.197
  19. Im JH, Seong J, Lee J, et al. Postoperative radiotherapy dose correlates with locoregional control in patients with extrahepatic bile duct cancer. Radiat Oncol J 2014;32:7-13. https://doi.org/10.3857/roj.2014.32.1.7
  20. Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788-97. https://doi.org/10.1097/00000658-199506000-00017

피인용 문헌

  1. Surgery Alone Versus Surgery Followed by Chemotherapy and Radiotherapy in Resected Extrahepatic Bile Duct Cancer: Treatment Outcome Analysis of 336 Patients vol.48, pp.2, 2014, https://doi.org/10.4143/crt.2015.091
  2. Postoperative radiotherapy appeared to improve the disease free survival rate of patients with extrahepatic bile duct cancer at high risk of loco-regional recurrence vol.34, pp.4, 2014, https://doi.org/10.3857/roj.2016.01879
  3. Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer vol.79, pp.6, 2014, https://doi.org/10.1007/s00280-017-3312-y
  4. Predictive factors of gastroduodenal bleeding after postoperative radiotherapy in biliary tract cancer vol.47, pp.4, 2014, https://doi.org/10.1093/jjco/hyw205
  5. Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution vol.49, pp.2, 2017, https://doi.org/10.4143/crt.2016.166
  6. Clinical Outcomes of Salvage Chemoradiotherapy for Locally Recurrent Biliary Tract Cancer vol.103, pp.4, 2014, https://doi.org/10.5301/tj.5000666
  7. Prognostic value of carbohydrate antigen 19‐9 in patients undergoing resection of biliary tract cancer vol.104, pp.3, 2014, https://doi.org/10.1002/bjs.10415
  8. Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery vol.90, pp.1080, 2017, https://doi.org/10.1259/bjr.20170308
  9. The impact of perioperative CA19‐9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma vol.117, pp.3, 2014, https://doi.org/10.1002/jso.24856
  10. High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients vol.44, pp.5, 2014, https://doi.org/10.1016/j.ejso.2018.01.012
  11. Risk factors associated with locoregional failure and estimation of survival after curative resection for patients with distal bile duct cancer vol.9, pp.None, 2014, https://doi.org/10.1038/s41598-019-41622-2
  12. Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for “Borderline Resectable” in the Field of Surgery for Hilar Cholangiocarcinoma vol.43, pp.4, 2014, https://doi.org/10.1007/s00268-018-04883-y
  13. Radiation therapy for extrahepatic bile duct cancer: Current evidences and future perspectives vol.7, pp.11, 2019, https://doi.org/10.12998/wjcc.v7.i11.1242
  14. Retrospective analysis of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy of postoperative treatment for biliary tract cancer vol.37, pp.4, 2019, https://doi.org/10.3857/roj.2019.00430
  15. Utility of Endoscopic Ultrasound-Guided Fine Needle Aspiration in the Diagnosis of Local Recurrence of Pancreaticobiliary Cancer after Surgical Resection vol.14, pp.5, 2014, https://doi.org/10.5009/gnl19200
  16. Prognostic Impact of Perioperative CA19-9 Levels in Patients with Resected Perihilar Cholangiocarcinoma vol.10, pp.7, 2014, https://doi.org/10.3390/jcm10071345